CSF Biomarker Comparison Across Neurodegenerative Diseases

Overview

Cerebrospinal fluid (CSF) biomarkers provide direct molecular insights into central nervous system pathology and are essential for differential diagnosis of neurodegenerative diseases. This page compares key CSF biomarkers across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD)[@blennow2020][@simonsen2022].

Core CSF Biomarker Classes

1. Tau-Related Biomarkers

Overview

Cerebrospinal fluid (CSF) biomarkers provide direct molecular insights into central nervous system pathology and are essential for differential diagnosis of neurodegenerative diseases. This page compares key CSF biomarkers across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD)[@blennow2020][@simonsen2022].

Core CSF Biomarker Classes

1. Tau-Related Biomarkers

Total Tau (t-Tau)

• What it measures: Total tau protein reflecting neuronal injury
• AD: Elevated (sensitivity ~80%, specificity ~70%)
• PD: Typically normal or mildly elevated
• ALS: Elevated in advanced disease
• FTD: Variable, often normal in pure FTD

Phosphorylated Tau (p-Tau)

• What it measures: Hyperphosphorylated tau indicating NFT pathology
• p-Tau181: Most established, AD-specific (sensitivity 85%, specificity 85%)[@hansson2022]
• p-Tau217: Highest accuracy for AD (sensitivity 90%, specificity 88%)[@palmqvist2021]
• p-Tau231: Earliest detector in preclinical AD[@janelidze2020]

2. Amyloid Biomarkers

Aβ42/Aβ40 Ratio

• What it measures: Amyloid plaque pathology
• AD: ↓ Aβ42, ↓ Aβ40 ratio (sensitivity 80%, specificity 75%)[@schindler2022]
• PD: Typically normal
• ALS: Typically normal
• FTD: Normal in pure FTD; may be abnormal with AD comorbidity

3. Neurodegeneration Markers

Neurofilament Light Chain (NfL)

• What it measures: Neuroaxonal injury severity
• AD: Moderately elevated
• PD: Elevated in PD with dementia (PDD)
• ALS: Markedly elevated (strongest marker for ALS)[@benatar2022]
• FTD: Elevated, correlates with disease progression

Neurogranin (Ng)

• What it measures: Synaptic degeneration
• AD: Strongly elevated
• PD: Mild elevation
• ALS: Elevated
• FTD: Variable

4. Synuclein Biomarkers

Alpha-Synuclein

• What it measures: Alpha-synuclein pathology
• Total α-syn: Decreased in synucleinopathies[@parnetti2019]
• Real-time quaking-induced conversion (RT-QuIC): Positive in ~95% of PD, ~55% of AD
• PD: ↓ Total, RT-QuIC often positive
• DLB: ↓ Total, RT-QuIC positive
• AD/ALS/FTD: Typically normal

5. TDP-43 Biomarkers

TDP-43

• What it measures: TDP-43 proteinopathy
• ALS: Elevated in CSF (sensitivity ~75%, specificity ~80%)[@kasai2020]
• FTD: Elevated, especially in ALS-FTD spectrum
• AD/PD: Typically normal

6. Glial Markers

Glial Fibrillary Acidic Protein (GFAP)

• What it measures: Astrocyte activation
• AD: Elevated
• PD: Typically normal
• ALS: Elevated
• FTD: Variable

Diagnostic Utility by Disease

Alzheimer's Disease (AD)

• Aβ42/Aβ40 ratio: Best for identifying amyloid pathology
• p-Tau217: Highest discriminative accuracy vs. other dementias
• NfL: Correlates with disease progression
• Neurogranin: Specific marker of synaptic dysfunction[@lista2015]

Parkinson's Disease (PD)

• α-syn RT-QuIC: Sensitive for prodromal PD
• NfL: Prognostic marker for cognitive decline
• p-Tau/NfL ratio: May distinguish PD from atypical parkinsonism

Amyotrophic Lateral Sclerosis (ALS)

• NfL: Strongest diagnostic and prognostic biomarker[@benatar2022]
• pNfH: Correlates with disease progression
• TDP-43: Reflects pathological burden
• Chitinase-3-like protein 1 (YKL-40): Elevated, marker of neuroinflammation

Frontotemporal Dementia (FTD)

• NfL: Correlates with disease severity
• YKL-40: Elevated in some subtypes
• Progranulin: Genetic forms have distinct profiles

Cross-Disease Comparison

| Biomarker | AD | PD | ALS | FTD |
|-----------|-----|------|------|------|
| Aβ42/Aβ40 | ↓↓ | ↔ | ↔ | ↔ |
| p-Tau181 | ↑↑ | ↔ | ↔ | ↔ |
| p-Tau217 | ↑↑ | ↔ | ↔ | ↔ |
| t-Tau | ↑↑ | ↔/↑ | ↑ | ↔/↑ |
| NfL | ↑ | ↔/↑ | ↑↑↑ | ↑/↑↑ |
| α-syn (total) | ↓ | ↓↓ | ↔ | ↔ |
| TDP-43 | ↔ | ↔ | ↑↑ | ↑ |
| GFAP | ↑ | ↔ | ↑ | ↔/↑ |
| Neurogranin | ↑↑ | ↑ | ↑ | ↔/↑ |

Biomarker Panels for Differential Diagnosis

AD vs. FTD vs. ALS

• AD: Aβ42/Aβ40↓ + p-Tau↑↑ + t-Tau↑
• FTD: Aβ42/Aβ40↔ + p-Tau↔ + NfL↑ + TDP-43↔
• ALS: NfL↑↑↑ + TDP-43↑ + p-Tau↔

PD vs. Atypical Parkinsonism (PSP/CBS)

• PD: α-syn↓ + NfL↔/↑ + p-Tau↔
• PSP/CBS: NfL↑↑ + p-Tau↔ + t-Tau↑

Clinical Applications

Diagnostic Workup

Prognostic Markers

• NfL: Strongest prognostic marker across all diseases
• p-Tau: Correlates with cognitive decline in AD
• Neurogranin: Predicts cognitive progression in AD

Monitoring Therapeutic Response

• NfL: Used as outcome in ALS clinical trials
• p-Tau: Reduced by anti-amyloid therapies in AD trials[@blennow2023]

Limitations

• Assay variability: Different platforms have different cutoffs
• Overlap: Biomarkers can be elevated in multiple conditions
• Sensitivity/specificity: No single biomarker is pathognomonic
• Dynamic range: Some biomarkers have ceiling effects
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

References

Pathway Diagram

The following diagram shows the key molecular relationships involving CSF Biomarker Comparison Across Neurodegenerative Diseases discovered through SciDEX knowledge graph analysis: